Hybio Pharmaceutical and Huawei Cloud Sign Comprehensive Cooperation Agreement, Focusing on "AI-powered Drug Discovery" to Promote Intelligent Upgrades in the Pharmaceutical Industry
On April 27, 2025, Shenzhen Hybio Pharmaceutical Co., Ltd. and Huawei Cloud Computing Technologies Co., Ltd. held a signing ceremony for a comprehensive cooperation agreement at Huawei's Bantian Base in Shenzhen. Tang Yangming, Director and Vice President of Hybio Pharmaceutical, and Chen Hang, Head of Huawei Cloud's Shenzhen Business Department, signed the agreement on behalf of both parties.
Present at the signing ceremony were Zeng Shaogui, Chairman and President of Hybio Pharmaceutical; Yu Pinxiang, Director and Executive President; Xu Liyong, Independent Director; Yang Di, Director and Vice President; Dr. Chen Jiantao, Manager of R&D and Innovation Department; Lin Ruibin, Manager of Enterprise Management and Information Department; as well as Li Shi, President of Huawei Cloud Computing Global Sales Department; Fan Yanping, Deputy Head of Huawei Cloud's Shenzhen Business Department, and other leaders. Both parties conducted in-depth discussions on the cooperation content.
Chen Hang, Head of Huawei Cloud's Shenzhen Business Department, and Tang Yangming, Director and Vice President of Hybio Pharmaceutical, signed the Comprehensive Cooperation Agreement on behalf of both parties.
The launch of this comprehensive cooperation is of far-reaching significance, marking that Huawei Cloud will assist Hybio Pharmaceutical in taking "AI-powered Drug Discovery" as the core direction, and carry out full-chain and in-depth innovation around peptide and oligonucleotide drug research and development, thereby enabling the pharmaceutical industry to achieve both qualitative and efficiency improvements in the era of artificial intelligence.
Going forward, both parties will collaborate in areas such as drug research and development, application of AI large models, digital platform construction, data governance, and AI talent empowerment.
In terms of drug research and development, the two parties will jointly develop large models for peptide and oligonucleotide drug R&D. Hybio Pharmaceutical will leverage Huawei Cloud's Pangu pharmaceutical molecule large model and various advanced large models, which excel in data processing and deep learning, combined with its own profound accumulation in drug R&D. It aims to achieve breakthroughs in core links such as molecular design and screening, API process development, optimization of analytical methods, and clinical trial design, so as to accelerate the new drug R&D process and improve efficiency and success rate.
In the application of AI large models, based on Huawei Cloud's AI technology applications, efforts will be made to promote intelligent upgrading in Hybio Pharmaceutical's core business scenarios including sales, production, finance, administration, and human resources. This will help build an intelligent operation system and facilitate the enterprise's comprehensive digital and intelligent transformation.
In addition, the two parties will carry out extensive cooperation in digital platform construction, data governance, and the cultivation of AI-empowered talents, jointly creating an intelligent collaborative ecosystem covering technology, data, scenarios, and capabilities.
As a leading enterprise in China's Peptide Drug R&D field, Hybio Pharmaceutical has always adhered to technology-driven innovation and digital-intelligent empowerment for development. The comprehensive cooperation with Huawei Cloud this time is not only an active exploration of the application of artificial intelligence technology in the pharmaceutical industry, but also a pragmatic action to implement the strategies of "Healthy China" and "Digital China".
On April 24, seven departments including the Ministry of Industry and Information Technology jointly released the Implementation Plan for Digital and Intelligent Transformation of the Pharmaceutical Industry (2025-2030), which clearly states that by 2030, the pharmaceutical industry will fully realize the whole-chain digital and intelligent upgrading, build more than 10 innovative platforms for pharmaceutical large models, and promote the in-depth integration and application of artificial intelligence in the pharmaceutical industry chain. The strong alliance between Hybio Pharmaceutical and Huawei Cloud is a major practice in actively responding to national policy calls and comprehensively promoting the coordinated development of "AI + pharmaceuticals", demonstrating the far-reaching layout of both parties in technological innovation and industrial upgrading.
Hybio Pharmaceutical will continue to uphold the development concept of openness, collaboration and innovation, and work with upstream and downstream industrial partners and technical ecological partners to jointly create a new paradigm of integrated development of "AI-powered drug discovery", and promote the high-quality development of China's pharmaceutical industry to a new level.